We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

The Use of Continuous Wound Infusion Analgesia in Total Knee Arthroplasty

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2008 by Capital Health, Canada.
Recruitment status was:  Not yet recruiting
ClinicalTrials.gov Identifier:
First Posted: July 29, 2008
Last Update Posted: July 29, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Capital Health, Canada
The main purpose of this study is to determine if there is improvement in pain and other patient outcomes when using a continuous wound analgesia system after total knee replacement, compared to usual methods of pain control. Another purpose is to determine if the system makes it easier for nurses to care for these patients.

Condition Intervention
Total Knee Arthroplasty Device: On-Q PainBuster with Bupivacaine Device: Usual Care

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Use of Continuous Wound Infusion Analgesia in Total Knee Arthroplasty

Resource links provided by NLM:

Further study details as provided by Capital Health, Canada:

Primary Outcome Measures:
  • Pain, measured by the 11-point numerical pain rating scale [ Time Frame: Post-operatively for three days then again at follow-up ]

Secondary Outcome Measures:
  • Post-operative nausea and vomiting [ Time Frame: Post-operatively for three days ]
  • Narcotic medications taken [ Time Frame: Post-operatively for three days ]
  • Time to first mobilization, first transfer and first 30-M walk [ Time Frame: Up to three days post-operatively ]
  • Number of adverse events [ Time Frame: Three days post-op (observed) then at follow-up (self-report) ]
  • Length of Stay [ Time Frame: Time of surgery to discharge ]
  • Satisfaction (patient and caregiver) [ Time Frame: Discharge from hospital ]

Estimated Enrollment: 20
Arms Assigned Interventions
Experimental: S
Patients receive the On-Q local continuous wound infusion system intra-operatively and use it for up to three days post-operatively.
Device: On-Q PainBuster with Bupivacaine
On-Q PainBuster continuous wound infusion analgesia system, using bupivacaine as the local anaesthetic
Active Comparator: C
Usual care - post operative pain medications as per the knee arthroplasty care map.
Device: Usual Care
Usual Care

Detailed Description:

Continuous local wound infusion analgesia is a relatively new way of managing post-operative pain, whereby a local anesthetic is continuously infused into the surgical area. Some studies and users have reported decreased pain, decreased opioid use, decreased post-operative nausea and vomiting, decreased length of stay, and improved patient and caregiver satisfaction with the use of continuous local wound infusion analgesia, when compared to placebo, or usual care, in arthroplasty and other surgical interventions.



The On-Q PainBuster (continuous wound infusion analgesia) in TKA will result in improved patient pain control, compared to usual care.


  • Pain scores post-operatively will be better than usual care.
  • Fewer narcotics will be ingested post-operatively than with usual care.
  • Post-op nausea and vomiting will be less than usual care.
  • Length of stay will be shorter compared to usual care.
  • Patient satisfaction will be greater than satisfaction with usual care.
  • Post-operative infection rates will be no different between groups.
  • Fall rates will be no different between groups.
  • Subjects will participate in physical therapy the day of surgery.
  • Nursing Intensity requirements will be less with the wound infusion due to fewer requests for pain medication.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 69 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Scheduled for TKA at the Royal Alexandra Hospital
  • Patient of Dr. Arnett
  • Deemed fit for continuous wound infusion (no allergies to Bupivacaine or related medications) by anesthesia
  • Cognitively aware, and provides informed consent
  • Elective (not trauma-related) surgery
  • Able to read, speak and understand English
  • Adult < 70 years of age
  • Intra-operative spinal anaesthesia
  • Reside within metropolitan Edmonton, in a bungalow
  • Have a caregiver at home
  • ASA risk classification of 1 or 2
  • Do not regularly use opioid medication pre-operatively
  • Have preoperative knee range of motion > 90 degrees
  • Body Mass Index < 40
  • No known hepatic or liver insufficiency

Exclusion Criteria:

  • Deemed unfit for continuous wound infusion due to allergies
  • Other exclusion criteria to be determined
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00724074

Contact: Holly Meyer, MSc 780-735-1119 holly.meyer@capitalhealth.ca
Contact: Gordon Arnett, MD 780-455-5115 garnett@edmontonortho.ca

Canada, Alberta
Royal Alexandra Hospital Not yet recruiting
Edmonton, Alberta, Canada
Principal Investigator: Gordon Arnett, MD         
Sponsors and Collaborators
Capital Health, Canada
Principal Investigator: Gordon Arnett, MD Capital Health, Canada
  More Information

Responsible Party: Dr. Gordon Arnett, Capital Health
ClinicalTrials.gov Identifier: NCT00724074     History of Changes
Other Study ID Numbers: garnett
First Submitted: July 25, 2008
First Posted: July 29, 2008
Last Update Posted: July 29, 2008
Last Verified: July 2008

Keywords provided by Capital Health, Canada:
Arthritis of the knee
Knee replacement
Osteoarthritis, knee
Arthroplasty, knee

Additional relevant MeSH terms:
Anesthetics, Local
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents